开放与机器人辅助腹腔镜前列腺癌根治术八年随访:功能与肿瘤学结局
这项前瞻性多中心非随机对照研究纳入瑞典14中心4003例局限性前列腺癌患者,比较RALP与RRP术后8年结局。RALP组尿失禁与RRP组无显著差异,勃起功能障碍显著更低,前列腺癌特异性死亡率显著更低。
要点
- RALP与RRP术后8年尿失禁无显著差异(27% vs 29%)。
- RALP组勃起功能障碍显著低于RRP组(66% vs 70%)。
- RALP组前列腺癌特异性死亡率显著更低(aRR 0.56)。
核心结论
- RALP术后8年前列腺癌特异性死亡率低于RRP,但无法推断手术方式与死亡率的因果关系。
- 结果证实RALP在肿瘤学上是安全的,支持继续实施RALP。
研究设计与样本
- 前瞻性、对照、非随机试验,2008至2011年瑞典14个中心纳入4003例患者,比较RALP与RRP。
- 功能结局通过术前及术后12、24个月和8年的 validated 患者问卷评估。
主要发现
- 术后8年尿失禁RALP组27% vs RRP组29%,aRR 1.05(95%CI 0.90-1.23),无显著差异。
- 勃起功能障碍RALP组66% vs RRP组70%,aRR 0.93(95%CI 0.87-0.99),RALP组显著更低。
- 前列腺癌特异性死亡RALP组40/2699 vs RRP组25/885,aRR 0.56(95%CI 0.34-0.93),RALP组显著更低。
- 高D'Amico风险组中,RALP vs RRP切缘阳性21% vs 34%,生化复发51% vs 69%,前列腺癌特异性死亡14/220 vs 11/77。
关键数值与推荐
- 主要终点为尿失禁,8年功能结局采用modified Poisson回归分析。
- 高D'Amico风险组切缘阳性率RALP 21% vs RRP 34%,生化复发率51% vs 69%。
临床怎么用
- 对于局限性前列腺癌,RALP在长期肿瘤学安全性上不劣于RRP,且勃起功能结局更优。
- 高D'Amico风险患者选择RALP可能降低切缘阳性、生化复发和前列腺癌特异性死亡风险。
局限性
- 主要局限性为非随机化设计,无法排除混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radical prostatectomy reduces mortality among patients with localised prostate cancer. Evidence on whether different surgical techniques can affect mortality rates is lacking. OBJECTIVE: To evaluate functional and oncological outcomes 8 yr after robot-assisted laparoscopic prostatectomy (RALP) and open retropubic radical prostatectomy (RRP). DESIGN, SETTING, AND PARTICIPANTS: We enrolled 4003 patients in a prospective, controlled, nonrandomised trial comparing RALP and RRP in 14 Swedish centres between 2008 and 2011. Data for functional outcomes were assessed via validated patient questionnaires administered preoperatively and at 12 and 24 mo and 8 yr after surgery. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was urinary incontinence. Functional outcomes at 8 yr were analysed using the modified Poisson regression approach. RESULTS AND LIMITATIONS: Urinary incontinence was not significantly different at 8 yr after surgery between RALP and RRP (27% vs 29%; adjusted risk ratio [aRR] 1.05, 95% confidence interval [CI] 0.90-1.23). Erectile dysfunction was significantly lower in the RALP group (66% vs 70%; aRR 0.93, 95% CI 0.87-0.99). Prostate cancer-specific mortality (PCSM) was significantly lower in the RALP group at 8 yr after surgery (40/2699 vs 25/885; aRR 0.56, 95% CI 0.34-0.93). Differences in oncological outcomes were mainly seen in the group with high D'Amico risk, with a lower risk of positive surgical margins (21% vs 34%), biochemical recurrence (51% vs 69%), and PCSM (14/220 vs 11/77) for RALP versus RRP. The main limitation is the nonrandomised design. CONCLUSIONS: In this prospective multicentre controlled trial, PCSM at 8 yr after surgery was lower for RALP in comparison to RRP. A causal relationship between surgical technique and mortality cannot be inferred, but the result confirms that RALP is oncologically safe. Taken together with better short-term results reported elsewhere, our findings confirm that implementation of RALP may continue. PATIENT SUMMARY: Our study comparing two surgical techniques for removal of the prostate for localised prostate cancer shows that a robot-assisted minimally invasive technique is safe in the long term. Together with previous results showing some better short-term effects with this approach, our findings support continued use of robot-assisted surgery.
引用
- Lantz A, Bock D, Akre O, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol. 2021. PMID: 34538508. doi:10.1016/j.eururo.2021.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。